Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- Pipeline
With a strong focus on difficult-to-treat diseases, our...
- News Releases
Biogen News Releases and Company Statements. Sage...
- Contact Us
Alzheimer’s Support Alzheimer’s Support Services...
- Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a complex, heterogeneous, chronic...
- Leadership Team
Meet our executive leadership team. Inspired by the science:...
- Investor Relations
Biogen. Corporate Profile. Founded in 1978, Biogen is a...
- Responsibility
For Biogen, that includes bolstering our commitment to...
- Alzheimer's Disease
Biogen has signed agreements with the National Association...
- Pipeline
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Jan 7, 2023 · Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full FDA approval of the drug. The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aim to...
Biogen News Releases and Company Statements. Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor. “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel.
People also ask
Who is Biogen?
Who is Biogen & why should you care?
Is Biogen a drug candidate?
Is Biogen a stock?
